Clinical trials: PLATELET AGGREGATION
Systolic Heart Failure
Platelet Inhibition in Patients With Systolic Heart Failure
The investigators aim to determine if patients with systolic heart failure treated with prasugrel achieve greater platelet inhibition compared to those treated with clopidogrel.
- Trial name
- NCT01765400
- Testing
- Prasugrel 10 mg daily x 2 weeks, Clopidogrel 75 mg daily x 2 weeks
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Nebraska
Healthy
A Study of the Effects of Multiple Doses of Dexlansoprazole, Lansoprazole, Omeprazole or Esomeprazole on the Pharmacokinetics and Pharmacodynamics of Clopidogrel in Healthy Participants.
The purpose of this study is to assess the potential effect and safety of multiple oral doses of dexlansoprazole, lansoprazole, omeprazole or esomeprazole, once daily (QD), on the steady-state pharmacokinetics and…
- Trial name
- NCT00942175
- Testing
- Clopidogrel, Clopidogrel and Lansoprazole, Clopidogrel and Dexlansoprazole
- Where
- United States
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Takeda
Platelet Dysfunction
The Effect of Dapagliflozin on Platelet Function testinG Profiles in Diabetic PatiEnts.
Sodium GLucose Transport 2 inhibitors (SGLT2I), including dapagliflozin, reduce the likelihood of hospitalization for heart failure and death in persons with type 2 diabetes, of which the mechanism has not been fully elucidated.
- Trial name
- EDGE (NCT04400760)
- Testing
- DAPA Tx
- Where
- Trinidad and Tobago
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- The University of The West Indies
Thrombocytopenia, Myocardial Infarction
Aspirin in Patients With Myocardial Infarction and Thrombocytopenia
Primary Objective: To determine the risk of bleeding from ASA therapy in thrombocytopenic patients who develop Acute Coronary Syndrome (ACS), and assess its effect on the overall morbidity and mortality in these patients as well…
- Trial name
- NCT00501345
- Testing
- Aspirin
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- M.D. Anderson Cancer Center
Chronic Kidney Disease
Whole Blood Platelet Aggregation in Chronic Kidney Disease Patients on Aspirin Study
Higher coronary in-stent thromboses and bleeding complications on anti-platelet agents are more common in Chronic Kidney Disease vs. non-Chronic Kidney Disease patients.
- Trial name
- WiCKDonASA (NCT01768637)
- Testing
- Aspirin, Clopidogrel
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- University of Texas Southwestern Medical Center
Aortic Valve Disease
Transcranial Doppler (TCD) Assessment During Early Anti-thrombotic Therapy After Bioprosthetic Aortic Valve Replacement
The purpose of this study is to determine if there is any difference in the counts of cerebral emboli and platelet function between two prophylactic treatments of thrombosis currently used at University of Ottawa Heart Institute…
- Trial name
- Tissue-Valve (NCT00465218)
- Testing
- Prophylaxis of Thrombosis after aortic valve replacement
- Where
- Canada
- Volunteers
- 70 people
- Sponsor
- Ottawa Heart Institute Research Corporation
Cardiovascular Disease
Postprandial Effects of Walnut Components Versus Whole Walnuts on Cardiovascular Disease (CVD) Risk Reduction
The purpose of this study is to evaluate the acute, postprandial effects and mechanism of action of various walnut components (separated nut skins, de-fatted nut meat, nut oil) versus whole walnuts on oxidative stress…
- Trial name
- NCT00938340
- Testing
- Walnut "meat", Walnut Oil, Walnut Skins
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Penn State University
Coronary Artery Disease, Chest Pain
The Effect of Clopidogrel on Coated-Platelets in Patients Undergoing Cardiac Catheterization
This study will explore the effect of clopidogrel on coated-platelets in patients who are given a loading dose before diagnostic catheterization or percutaneous coronary intervention.
- Trial name
- NCT00644657
- Testing
- Clopidogrel
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- University of Oklahoma
Platelet Aggregation Inhibitors, Coronary Heart Disease
Determining Genetic Role in Treatment Response to Anti-Platelet Interventions (The PAPI Study)
One of the most common ways for preventing coronary heart disease (CHD) is to take aspirin or clopidogrel. However, studies have shown that not all people respond to these medications.
- Trial name
- NCT00799396
- Testing
- Clopidogrel, Aspirin
- Where
- United States
- Volunteers
- 682 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Wiskott-Aldrich Syndrome, Thrombocytopenia
Thrombocytopenia and Bleeding in Wiskott-Aldrich Syndrome (WAS) Patients
The purpose of this project is to describe the pathophysiology of thrombocytopenia and bleeding in patients with Wiskott-Aldrich Syndrome (WAS) and determine the response to thrombopoietic agents in vitro and in vivo.
- Conditions
- Wiskott-Aldrich Syndrome, Thrombocytopenia, Bleeding
- Trial name
- WAS (NCT00909363)
- Testing
- Promacta, blood drawing in patients with WAS, blood drawing in healthy controls
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Weill Medical College of Cornell University
Pulmonary Arterial Hypertension
A Study With BPS-314d-MR-PAH-303 in Participants With Pulmonary Arterial Hypertension
This is a multi-center, open-label study for eligible participants who were actively participating in the BPS-314d-MR-PAH-302 double-blind study (NCT01908699) at the time the study was concluded.
- Trial name
- BEAT OLE (NCT03657095)
- Testing
- Esuberaprost
- Where
- 45 sites in United States, Israel
- Volunteers
- 112 people
- Sponsor
- Lung Biotechnology PBC
Coronary Artery Disease
High Ticagrelor Loading Dose in STEMI
Ticagrelor is a reversible direct acting P2Y12 antagonist, which has shown to be superior to clopidogrel, in adjunct to aspirin, in preventing recurrent ischemic events.
- Trial name
- NCT01898442
- Testing
- Ticagrelor 180mg, Ticagrelor 270mg, Ticagrelor 360mg
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- University of Florida
Coronary Artery Disease
Impact of Ticagrelor Re-load on Pharmacodynamic Profiles
Platelets are parts of your blood that stick together to help form a clot. The stickier your platelets are, the greater your chance of having a heart attack. A clot in the wrong place can lead to a heart attack or stroke.
- Trial name
- NCT01731041
- Testing
- Ticagrelor 180mg, Ticagrelor 90mg
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of Florida
Stroke, Myocardial Infarctions
Aspirin Resistance and Stroke Risk: Platelet Function Analysis in Patients With Ischemic Events
The purpose of this study is to determine if PFA results correlate with ischemic event outcomes as well as bleeding complications.
- Trial name
- NCT01586975
- Testing
- Clopidogrel, Aspirin 81 mg, Aspirin >300 mg
- Where
- United States
- Volunteers
- 93 people
- Sponsor
- Northwestern University
Blood Platelets, Clopidogrel
PACT (Platelet Activity After Clopidogrel Termination)
Clopidogrel is a medication that is used to decrease the ability of platelets to form blood clots. The theory has been proposed that, in patients with coronary artery disease or stroke, increased platelet function after…
- Trial name
- PACT (NCT00619073)
- Testing
- clopidogrel + aspirin, Aspirin
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- University of Massachusetts, Worcester
Coronary Artery Disease
Effect of Prasugrel Versus Clopidogrel on Platelet Function After Bivalirudin Cessation
Early stent thrombosis has been noted with increased frequency in acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI) who are treated with bivalirudin and clopidogrel.
- Trial name
- NCT01789814
- Testing
- Prasugrel, Clopidogrel
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Tufts Medical Center
Cardiovascular Risk Factor
Consumption of Oral Artificial Sweeteners on Platelet Aggregation and Polyol Excretion
The principal goal for the study is to examine whether ingestion of a beverage containing artificial sweeteners alters in vitro platelet aggregation.
- Trial name
- COSETTE (NCT04731363)
- Testing
- xylitol, 30g, erythritol, 30g, xylitol, 5g
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- The Cleveland Clinic
Drug Interaction
PPI and Clopidogrel Response
Clopidogrel, in combination with aspirin, is currently the recommended treatment for secondary prevention of ischemic events in high-risk patients and for prevention of coronary artery stent thrombosis.
- Trial name
- NCT01170533
- Testing
- omeprazole and pantoprazole
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University of Florida
Myocardial Infarction
The Effects of Lovaza® in Acute Myocardial Infarction
This study will explore the safety and effectiveness of adding Lovaza® to the therapeutic program utilized internationally for the treatment of individuals with acute coronary syndromes.
- Trial name
- OmegaMI (NCT01155336)
- Testing
- Lovaza®
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of Rochester
Cardiovascular Diseases, Acute Coronary Syndrome
Pharmacogenomics of Anti-platelet Intervention-2 (PAPI-2) Study
It is standard treatment to take anti-platelet medication after cardiac catheterization and stent placement to help prevent the formation of blood clots that may cause heart attack or stroke.
- Trial name
- PAPI-2 (NCT01452152)
- Testing
- clopidogrel, prasugrel
- Where
- 5 sites in United States
- Volunteers
- 9 people
- Sponsor
- University of Maryland, Baltimore